{
    "Trade/Device Name(s)": [
        "KET-1 Blood Ketone Monitoring System"
    ],
    "Submitter Information": "Apex Biotechnology Corp.",
    "510(k) Number": "K182593",
    "Predicate Device Reference 510(k) Number(s)": [
        "K091547"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JIN"
    ],
    "Summary Letter Date": "December 18, 2018",
    "Summary Letter Received Date": "September 20, 2018",
    "Submission Date": "September 13, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1435"
    ],
    "Regulation Name(s)": [
        "Ketones (nonquantitative) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "\u03b2-hydroxybutyrate"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "KET-1 Blood Ketone Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric biosensor technology",
        "Enzymatic reaction using \u03b2-hydroxybutyrate dehydrogenase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for KET-1 Blood Ketone Monitoring System for self-testing of \u03b2-hydroxybutyrate in capillary whole blood.",
    "Indications for Use Summary": "For self-testing by people with diabetes at home to quantitatively measure \u03b2-hydroxybutyrate in fresh capillary whole blood as an aid to monitoring the effectiveness of diabetes control programs; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}